Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Radiotherapy in Limited Stage NK/T Cell Lymphoma
NCT04417166Phase 2Active, not recruiting
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by International Extranodal Lymphoma Study Group. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04417166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417166.